Therapies for multiple sclerosis have emerged over the last decades with the demonstration of efficacy of immunomodulating therapies that impact the course of early multiple sclerosis;  Immunosuppressive drugs such as mitoxantrone and cyclophosphamide; Beta-interferons; an MHC-binding protein that engages the T Cell Receptor (TCR), and glatiramer acetate (GA) are all such a class of therapy [12].
Since the market is split between drugs, there has been intense marketing for market share by pharmaceutical companies.  Much impetus has focused on companies competing to position a superior product.  Marketing devices have taken many forms including physician and lay advocates, advertising, educational programs and postmarketing studies.  There has been an array of claims and counterclaims as exchange [78]. Read more…